The two-year pilot project will provide near-immediate test results without the need samples being sent to laboratories.
It is part of the Welsh Government’s ongoing aim to make sure more people can access healthcare closer to home, in local communities and will help to target antibiotic prescribing, tackling the problem of resistance.
The project makes use of diagnostic equipment originally purchased during the pandemic, which has been upgraded and repurposed to test for multiple bacterial infections in community settings.
The project is being supported by £734,000 of Welsh Government funding and £500,000 from the INEOS Oxford Institute for Antimicrobial Research. Oxford University will be providing an independent evaluation of the project.
The Point of Care Testing (POCT) in Primary Care pilot will focus initially on C-Reactive Protein (CRP) testing, which helps clinicians identify bacterial infections and make more informed decisions about antibiotic prescribing.
More than 300 community pharmacies and GP practices in all seven health board areas in Wales have expressed an interest in participating in the trial, which also supports the global fight against antimicrobial resistance, recognised by the World Health Organisation as one of the leading threats to public health.
Cabinet Secretary for Health and Social Care Jeremy Miles said: "This is a unique opportunity for Wales to lead the way in embedding high-quality diagnostic testing in primary and community care.
“By bringing testing closer to where people live, we can improve health outcomes, reduce pressure on hospital services, and ensure more appropriate use of antibiotics."
Tenby residents face ongoing mobile coverage issues as 4G/5G mast bid is refused
Paul Davies challenges Welsh Government over West Wales health services
Carmarthenshire County Council gives update on former Wilko building plans
Carmarthenshire councillors to visit proposed house of multiple occupation site
The partnership with Oxford University will provide rigorous, independent evaluation of the trial's impact on antibiotic prescribing, patient outcomes, and cost-effectiveness. The research will also develop machine learning models to identify patients at risk of adverse outcomes.


Comments
We've recently changed our login process. If you have an account for commenting, you will need to re-register on the login window.
This article has no comments yet. Be the first to leave a comment.